Pengaruh Terapi Atorvastatin terhadap Kadar Glukosa Darah pada Pasien Stroke Iskemik dengan Diabetes Melitus yang Dirawat di Rumah Sakit
Bilah Samping Artikel
Isi Artikel Utama
Page: 2184-2193
Abstrak
Latar belakang: Penggunaan atorvastatin pada pasien stroke sebagai pencegahan primer dapat berisiko meningkatkan glukosa darah. Penelitian ini bertujuan menilai pengaruh atorvastatin terhadap perubahan kadar gula darah pada pasien stroke iskemik. Metode:Penelitian observasional analitik dengan desain retrospektif dilakukan pada 28 pasien stroke iskemik rawat inap di RS Bhayangkara Kota Kediri periode Maret–April 2024. Kriteria inklusi meliputi pasien berusia >15 tahun, memiliki riwayat diabetes melitus, menerima atorvastatin, serta memiliki data kadar gula darah sebelum dan 3 hari setelah terapi. Data dianalisis menggunakan uji Shapiro–Wilk untuk menilai normalitas dan uji paired sample t-test untuk menilai perubahan gula darah. Hasil: Sebanyak 64,29% pasien mengalami peningkatan gula darah, tetapi analisis statistik menunjukkan tidak terdapat perbedaan signifikan antara kadar gula darah sebelum dan sesudah pemberian atorvastatin (231,64 ± 99,039 vs 231,50 ± 61,425 mg/dL; Δ = –0,14 mg/dL; p = 0,993). Kesimpulan: Terapi atorvastatin tidak menunjukkan hubungan yang bermakna secara statistik terhadap perubahan kadar glukosa darah acak. Meskipun demikian, tingginya proporsi pasien yang mengalami peningkatan kadar glukosa darah mengindikasikan perlunya penelitian prospektif dengan jumlah sampel yang lebih besar untuk mengonfirmasi temuan ini.
Unduhan
Rincian Artikel
Artikel ini berlisensiCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Referensi
Prabhakaran S, Gonzalez NR, Zachrison KS, Adeoye O, Alexandrov AW, Ansari SA, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke 2026. https://doi.org/10.1161/STR.0000000000000513.
Coculescu BI, Stocheci CM, Ripszky Totan A, Coculescu EC. A statistical analysis of acute ischemic stroke before and during the COVID-19 pandemic. Rom J Med Pract 2022;17:41–6. https://doi.org/10.37897/RJMP.2022.1.7.
Zhang L, Lu H, Yang C. Global, regional, and national burden of stroke from 1990 to 2019: A temporal trend analysis based on the Global Burden of Disease Study 2019. Int J Stroke 2024;19:686–94. https://doi.org/10.1177/17474930241246955.
Hou S, Zhang Y, Xia Y, Liu Y, Deng X, Wang W, et al. Global, regional, and national epidemiology of ischemic stroke from 1990 to 2021. Eur J Neurol 2024;31. https://doi.org/10.1111/ene.16481.
Li X yu, Kong X meng, Yang C hao, Cheng Z feng, Lv J jie, Guo H, et al. Global, regional, and national burden of ischemic stroke, 1990–2021: an analysis of data from the global burden of disease study 2021. EClinicalMedicine 2024;75:102758. https://doi.org/10.1016/j.eclinm.2024.102758.
Feigin VL, Brainin M, Norrving B, Martins SO, Pandian J, Lindsay P, et al. World Stroke Organization: Global Stroke Fact Sheet 2025. Int J Stroke 2025;20:132–44. https://doi.org/10.1177/17474930241308142.
Kusuma Y, Venketasubramanian N, Kiemas LS, Misbach J. Burden of Stroke in Indonesia. Int J Stroke 2009;4:379–80. https://doi.org/10.1111/J.1747-4949.2009.00326.X.
Volpi JJ, Kasner SE, Neervoort J, Wolters LF, Louwsma T, Marti AK, et al. The annual economic burden of patent foramen ovale-associated stroke in the United States. J Stroke Cerebrovasc Dis 2025;34:108319. https://doi.org/10.1016/J.Jstrokecerebrovasdis.2025.108319.
Wang J, Chen M, Yang J. Impact of DRG Reform Policies on Hospitalization Costs of Stroke Patients in Western China: Wisdom from Traditional Chinese Medicine. Risk Manag Healthc Policy 2025;18:2401–11. https://doi.org/10.2147/RMHP.S525667.
Ministry of Health of the Republic of Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/394/2019 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Stroke. 2019.
Ciplak S, Adiguzel A, Deniz YZ, Aba M, Ozturk U. The Role of the Low-Density Lipoprotein/High-Density Lipoprotein Cholesterol Ratio as an Atherogenic Risk Factor in Young Adults with Ischemic Stroke: A Case—Control Study. Brain Sci 2023, Vol 13, Page 1180 2023;13:1180. https://doi.org/10.3390/BRAINSCI13081180.
McPherson R, Adreak N, Sharma A. Medications for Lipid Control: Statins vs Newer Drugs. Can J Cardiol 2024;40:S26–34. https://doi.org/10.1016/j.cjca.2024.05.004.
Welch KM. Review of the SPARCL trial and its subanalyses. Curr Atheroscler Rep 2009;11:315–21. https://doi.org/10.1007/s11883-009-0048-0.
Sanossian N, Ovbiagele B. Drug Insight: translating evidence on statin therapy into clinical benefits. Nat Clin Pract Neurol 2008;4:43–9. https://doi.org/10.1038/ncpneuro0705.
Latif WD, Aswad M, Bahar MA. Perbandingan Efektivitas Klinik Simvastatin dan Atorvastatin Terhadap Profil Lipid Darah: Studi Kasus di Rumah Sakit Universitas Hasanuddin. J Sains Farm Klin 2022;9:34. https://doi.org/10.25077/jsfk.9.1.34-41.2022.
Zakyrjanova GF, Matigorova VA, Kuznetsova EA, Dmitrieva SA, Tyapkina O V., Tsentsevitsky AN, et al. Key genes and processes affected by atorvastatin treatment in mouse diaphragm muscle. Arch Toxicol 2025;99:2877–901. https://doi.org/10.1007/s00204-025-04056-6.
Sreenivasan A, KS L, Vijayan M, G Pai P. Atorvastatin induced liver injury: A Case Series. Res J Pharm Technol 2022:3507–10. https://doi.org/10.52711/0974-360X.2022.00588.
A Shoiab A, Gardouh A, Khwaldeh A, Alsarhan A. The Comparison Between the Effect of Atorvastatin and Nanoparticle Atorvastatin on Rat Liver. Biomed Pharmacol J 2023;16:237–41. https://doi.org/10.13005/bpj/2605.
Soliemanabad SK, Rasouli K, Zakariaei Z, Soleymani M, Aliabadi PK. Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction). Ann Med Surg 2022;75. https://doi.org/10.1016/j.amsu.2022.103384.
Putra MAP, Muhamad GS, Hendarti HF, Bhaskoro MFA, Kalaij GI. Risiko Diabetes Onset Baru pada Pemberian Terapi Statin: Kajian Literatur Populasi Asia. J Kesehat Tambusai 2023;4:4229–35. https://doi.org/https://doi.org/10.31004/jkt.v4i3.18719.
Widiarti W, Saputra PBT, Savitri CG, Putranto JNE, Alkaff FF. The impact of cardiovascular drugs on hyperglycemia and diabetes: a review of ‘unspoken’’ side effects.’ Hell J Cardiol 2025;83:71–7. https://doi.org/10.1016/j.hjc.2024.09.007.
Abbasi F, Lamendola C, Harris CS, Harris V, Tsai M-S, Tripathi P, et al. Statins Are Associated With Increased Insulin Resistance and Secretion. Arterioscler Thromb Vasc Biol 2021;41:2786–97. https://doi.org/10.1161/ATVBAHA.121.316159.
Sirvent P, Fabre O, Bordenave S, Hillaire-Buys D, Raynaud De Mauverger E, Lacampagne A, et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 2012;259:263–8. https://doi.org/10.1016/j.taap.2012.01.008.
Han KH. Functional Implications of HMG-CoA Reductase Inhibition on Glucose Metabolism. Korean Circ J 2018;48:951. https://doi.org/10.4070/kcj.2018.0307.
Wang L, Zheng Z, Zhu L, Meng L, Liu H, Wang K, et al. Geranylgeranyl pyrophosphate depletion by statins compromises skeletal muscle insulin sensitivity. J Cachexia Sarcopenia Muscle 2022;13:2697–711. https://doi.org/10.1002/jcsm.13061.
Kamisah Y, Nordin AH, Harafinova H-S, Nordin ML, Nurhidayah M, Muhammad NA, et al. Statin-associated new-onset diabetes mellitus and insulin resistance: a 30-year bibliometric study (1992-2022). Biomed Res Ther 2023;10:6035–48. https://doi.org/10.15419/bmrat.v10i11.845.
Cybulska B, Kłosiewicz-Latoszek L. How do we know that statins are diabetogenic, and why? Is it an important issue in the clinical practice? Kardiol Pol 2018;76:1217–23. https://doi.org/10.5603/KP.a2018.0150.
Kim J, Lee HS, Lee K-Y. Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. Cardiovasc Diabetol 2018;17:155. https://doi.org/10.1186/s12933-018-0799-4.
Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol 2014;8:S17–29. https://doi.org/10.1016/j.jacl.2014.02.012.
Liu Y, Shen Y, Guo T, Parnell LD, Westerman KE, Smith CE, et al. Statin Use Associates With Risk of Type 2 Diabetes via Epigenetic Patterns at ABCG1. Front Genet 2020;11. https://doi.org/10.3389/fgene.2020.00622.
Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, et al. Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients. J Investig Med 2009;57:495–9. https://doi.org/10.2310/JIM.0b013e318197ec8b.
Mansi IA, Chansard M, Lingvay I, Zhang S, Halm EA, Alvarez CA. Association of Statin Therapy Initiation With Diabetes Progression. JAMA Intern Med 2021;181:1562. https://doi.org/10.1001/jamainternmed.2021.5714.
Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia 2014;57:2444–52. https://doi.org/10.1007/s00125-014-3374-x.
Liew SM, Lee PY, Hanafi NS, Ng CJ, Wong SSL, Chia YC, et al. Statins use is associated with poorer glycaemic control in a cohort of hypertensive patients with diabetes and without diabetes. Diabetol Metab Syndr 2014;6:53. https://doi.org/10.1186/1758-5996-6-53.
Davis TME, Badshah I, Chubb SAP, Davis WA. Dose–response relationship between statin therapy and glycaemia in community‐based patients with type 2 diabetes: the F remantle D iabetes S tudy. Diabetes, Obes Metab 2016;18:1143–6. https://doi.org/10.1111/dom.12710.
Wandira E, Simamora S, Rulianti MR. Hubungan Penggunaan Obat Simvastatin Dengan Kadar Gula Darah Penderita Diabetes Mellitus Di Rs B hayangkara Palembang. Sel J Penelit Kesehat 2021;8:1–14. https://doi.org/10.22435/sel.v8i1.4705.
Heurtebize M-A, Faillie J-L. Drug-induced hyperglycemia and diabetes. Therapies 2024;79:221–38. https://doi.org/10.1016/j.therap.2023.09.010.
Mansoor H, Manion D, Kucharska-Newton A, Delcher C, Lo-Ciganic W-H, Jicha GA, et al. Sex Differences in Prescription Patterns and Medication Adherence to Guideline-Directed Medical Therapy Among Patients With Ischemic Stroke. Stroke 2025;56:318–25. https://doi.org/10.1161/Strokeaha.124.048058.
Kim JT, Lee JS, Kim H, Kim BJ, Kang J, Lee KJ, et al. Comparative Effectiveness of Rosuvastatin Versus Atorvastatin in Acute Ischemic Stroke Treatment. J Am Hear Assoc 2025;14:38080. https://doi.org/10.1161/JAHA.124.038080.
Zhang H, Plutzky J, Shubina M, Turchin A. Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study. PLoS One 2016;11:e0155228. https://doi.org/10.1371/journal.pone.0155228.
Witting C, Azizi Z, Gomez SE, Zammit A, Sarraju A, Ngo S, et al. Natural language processing to identify reasons for sex disparity in statin prescriptions. Am J Prev Cardiol 2023;14:100496. https://doi.org/10.1016/j.ajpc.2023.100496.
Kiss PAJ, Uijl A, de Boer AR, Duk TCX, Grobbee DE, Hollander M, et al. Sex differences in the intensity of statin prescriptions at initiation in a primary care setting. Heart 2024;110:981–7. https://doi.org/10.1136/heartjnl-2023-323722.
Nanna MG, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, et al. Sex Differences in the Use of Statins in Community Practice. Circ Cardiovasc Qual Outcomes 2019;12. https://doi.org/10.1161/Circoutcomes.118.005562.
Gamboa CM, Colantonio LD, Brown TM, Carson AP, Safford MM. Race‐Sex Differences in Statin Use and Low‐Density Lipoprotein Cholesterol Control Among People With Diabetes Mellitus in the Reasons for Geographic and Racial Differences in Stroke Study. J Am Heart Assoc 2017;6. https://doi.org/10.1161/Jaha.116.004264.
Virani SS, Woodard LD, Ramsey DJ, Urech TH, Akeroyd JM, Shah T, et al. Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease. Am J Cardiol 2015;115:21–6. https://doi.org/10.1016/j.amjcard.2014.09.041.
Muck MA, Baessler A. Schlagen Frauenherzen anders? – Geschlechterunterschiede im Lipidmanagement. J Für Endokrinol Diabetol Und Stoffwechsel 2025;18:23–9. https://doi.org/10.1007/s41969-025-00263-9.
Wu Y, Zheng H, Hu S, Chen X, Chen Y, Liu J, et al. The impact of metabolic diseases and their comorbidities for stroke in a middle-income area of China: a case-control study. Int J Neurosci 2023;133:1055–63. https://doi.org/10.1080/00207454.2022.2042692.
Anwar MMU, Jahan SMS, Afrin S, Hossain MZ. Diabetic and Non-diabetic Subjects with Ischemic Stroke: Risk Factors, Stroke Topography and Hospital Outcome. J Med 2017;18:75–9. https://doi.org/10.3329/jom.v18i2.33684.
Amory CF, Weinberger J. Cerebrovascular Disease. Textb. Diabetes, Wiley; 2017, p. 673–82. https://doi.org/10.1002/9781118924853.ch46.
Qian Y, Chopp M, Chen J. Emerging role of microRNAs in ischemic stroke with comorbidities. Exp Neurol 2020;331:113382. https://doi.org/10.1016/j.expneurol.2020.113382.
Paolino AS, Garner KM. Effects of Hyperglycemia on Neurologic Outcome in Stroke Patients. J Neurosci Nurs 2005;37:130–5. https://doi.org/10.1097/01376517-200506000-00002.
Chan DC, Pang J, Watts GF. Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10? Curr Atheroscler Rep 2015;17:472. https://doi.org/10.1007/s11883-014-0472-7.
Sunjaya A, Sunjaya A, Halim S, Ferdinal F. Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes. Int J Angiol 2018;27:121–31. https://doi.org/10.1055/s-0036-1572523.
Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006;49:1881–92. https://doi.org/10.1007/s00125-006-0269-5.
S. Kostapanos M, L. Liamis G, J. Milionis H, S. Elisaf M. Do Statins Beneficially or Adversely Affect Glucose Homeostasis? Curr Vasc Pharmacol 2010;8:612–31. https://doi.org/10.2174/157016110792006879.
She J, Tuerhongjiang G, Guo M, Liu J, Hao X, Guo L, et al. Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner. Cell Metab 2024;36:408-421.e5. https://doi.org/10.1016/j.cmet.2023.12.027.
Huptas S, Geiss H-C, Otto C, Parhofer KG. Effect of Atorvastatin (10 mg/day) on Glucose Metabolism in Patients With the Metabolic Syndrome. Am J Cardiol 2006;98:66–9. https://doi.org/10.1016/j.amjcard.2006.01.055.
Bell DSH, DiNicolantonio JJ, O’Keefe JH. Is statin‐induced diabetes clinically relevant? A comprehensive review of the literature. Diabetes, Obes Metab 2014;16:689–94. https://doi.org/10.1111/dom.12254.
Bang CN, Okin PM. Statin Treatment, New-Onset Diabetes, and Other Adverse Effects: A Systematic Review. Curr Cardiol Rep 2014;16:461. https://doi.org/10.1007/s11886-013-0461-4.
Rocco MB. Statins and diabetes risk: Fact, fiction, and clinical implications. Cleve Clin J Med 2012;79:883–93. https://doi.org/10.3949/ccjm.79a.12091.
Thomson S, Chogtu B, Shetty R, Devasia T. Analysis of glycemic status in diabetes-naïve patients on statins: A hospital-based cross-sectional study. Indian J Pharmacol 2018;50:320. https://doi.org/10.4103/ijp.IJP_132_18.
Rius Tarruella J, Millán Núñez-Cortés J, Pedro-Botet J, Pintó Sala X. La diabetogenicidad de las estatinas: ¿son todas iguales? Estado de la cuestión. Clínica e Investig En Arterioscler 2015;27:148–58. https://doi.org/10.1016/j.arteri.2015.02.001.
Abboud N, Makhous R. The effect of some statins on Glucose blood levels in experimental animals. Res J Pharm Technol 2022:2661–6. https://doi.org/10.52711/0974-360X.2022.00445.
Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl 2015;16:1–27. https://doi.org/10.1016/S1567-5688(14)70002-9.
Al-Bayyari N, Saadeh N, Hailat R, Al-Zeidaneen S. Assessment of Atorvastatin Effect on Body Weight and Blood Glucose Levels Among Diabetic and Non-Diabetic Patients. Rom J Diabetes Nutr Metab Dis 2017;24:255–62. https://doi.org/10.1515/rjdnmd-2017-0031.
Deng Y, Zou W, Chen G, Shangguan S, Zhou F, Jiang W, et al. Comparative studies on the effects of different doses of atorvastatin combined with aspirin on inflammatory cytokines and carotid plaques in patients with ischemic cerebrovascular disease. Int J Neurosci 2019;129:1133–8. https://doi.org/10.1080/00207454.2019.1635592.
Nalini R, Ramya JE, Karthick R. Evaluation of glycemic status among hypercholesterolemic patients on atorvastatin in a tertiary care hospital – A retrospective study. Indian J Pharmacol 2022;54:165–70. https://doi.org/10.4103/ijp.ijp_943_20.
Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients. J Am Coll Cardiol 2010;55:1209–16. https://doi.org/10.1016/j.jacc.2009.10.053.
Hui J, Zhang J, Mao X, Li Z, Li X, Wang F, et al. The initial glycemic variability is associated with early neurological deterioration in diabetic patients with acute ischemic stroke. Neurol Sci 2018;39:1571–7. https://doi.org/10.1007/s10072-018-3463-6.
Cai Y, Wang C, Di W, Li W, Liu J, Zhou S. Correlation between blood glucose variability and the risk of death in patients with severe acute stroke. Rev Neurol (Paris) 2020;176:582–6. https://doi.org/10.1016/j.neurol.2019.12.003.
Gutiérrez-Zúñiga R, Alonso de Leciñana M, Delgado-Mederos R, Gállego-Cullere J, Rodríguez-Yáñez M, Martínez-Zabaleta M, et al. Más allá de la hiperglucemia: la variabilidad glucémica como factor pronóstico en el infarto cerebral agudo. Neurología 2023;38:150–8. https://doi.org/10.1016/j.nrl.2020.06.018.
Cai Y, Zhang H, Li Q, Zhang P. Correlation Between Blood Glucose Variability and Early Therapeutic Effects After Intravenous Thrombolysis With Alteplase and Levels of Serum Inflammatory Factors in Patients With Acute Ischemic Stroke. Front Neurol 2022;13. https://doi.org/10.3389/fneur.2022.806013.
Tambunan N, Prawesti AP, Nuraeni A. Hiperglikemia Pada Saat Masuk Rumah Sakit Sebagai Prediktor Sepsis Dan Penentu Hasil Klinis Pada Pasien Dewasa di ICU: Tinjauan Komprehensif. J Ners 2026;10:1761–9. https://doi.org/10.31004/jn.v10i1.54147.